Most Recent
DePuy class action group member appeals failed challenge to payout
A group member in a class action against Johnson & Johnson unit DePuy has filed an appeal after he lost a challenge to his compensation determination, 12 years after the case settled.
Junior doctors class actions settle with Victorian hospitals for $175M
A group of class actions against healthcare providers in Victoria that allegedly failed to pay junior doctors for overtime have settled for $175 million. 
Law firm defending junior doctors class actions might get a lot busier
Victorian healthcare providers facing class actions on behalf of junior doctors have turned to one law firm to lead their defence. And that firm might be about to get a lot busier.
Bayer class action wants to know bill for failed case before deciding on appeal
The plaintiff in an unsuccessful class action against Bayer over its Essure contraceptive device wants to see whether she can avoid paying costs in the case before deciding on whether to appeal the loss.
Lundbeck, Sandoz end long-running Lexapro patent war
Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.
Cosmetic surgery class action faces battle over plan to drop doctor from case
A class action against Sydney doctor Daniel Lanzer and several of his associates over alleged botched cosmetic surgeries wants to drop its claims against one doctor, but other defendants have taken issue.
Allergan may bring ‘state of the art’ defence in breast implants class action
US drug maker Allergan may defend a class action over recalled textured breast implants by arguing its knowledge of the alleged defects was limited by the state of scientific knowledge at the time the products were made.
Court invalidates Otsuka’s patent for injectable Abilify
Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker's top-selling antipsychotic Abilify.
Construction PRO
Charter Hall boosts social infrastructure REIT with $47M Clinipath buy
Real estate fund manager Charter Hall has paid $47 million to purchase a Clinipath Pathology lab in Perth, bolstering its social infrastructure investment trust.